The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne...
Please login or register first to view this content.
Login Register